Tellimer

ID : Medikaloka Hermina - Best performer among peers

HEAL’s 4Q20 NP grew by 367% yoy to Rp212bn, beating estimates. Robust sales growth of 63% yoy in 4Q20 was driven by higher revenue per patient. Company guides for double-digit sales and NP growth in 2021F. We tweaked our FY21-22F EPS by 12-22%, projecting 11%/15% FY21F sales/NP growth. Reiterate Add on HEAL with a higher TP. The company managed to have positive FCF in 2020, and we expect the trend to sustain going forward.


Most Viewed See latest
Disclosures

This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not con...

Full Tellimer disclaimers